| Referências: |
AYALA J, QUESADA A, VADILLO S, CRIADO J, PIRIZ S. Penicillin-binding proteins of Bacteroides fragilis and their role in the resistance to imipenem of clinical isolates. J Med Microbiol. 2005 Nov;54(Pt 11):1055-64.
GARCIA-CASTELLANOS R, MALLORQUI-FERNANDEZ G, MARRERO A, POTEMPA J, COLL M, GOMIS-RUTH FX. On the transcriptional regulation of methicillin resistance: MecI repressor in complex with its operator. J Biol Chem. 2004 Apr 23;279(17):17888-96. Epub 2004 Feb 11.
GNIADKOWSKI M. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms.Clin Microbiol Infect. 2001 Nov;7(11):597-608. Review.
LI L, XU B.Multivalent vancomycins and related antibiotics against infectious diseases. Curr Pharm Des. 2005;11(24):3111-24. Review.
LOHNER K, BLONDELLE SE. Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics.Comb Chem High Throughput Screen. 2005 May;8(3):241-56. Review.
SHAH AA, HASAN F, AHMED S, HAMEED A. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases
WRIGHT GD. Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev. 2005 Jul 29;57(10):1451-70.
ACAR, J. Rapid development of resistance to cefepime during treatment. Clin. Infect. Dis 1998; 26:1484-5.
DRLICA, K. Refining the fluorquinolones. ASM NEWS. 1999; 65(6) 410-5.
LIVERMORE, DM. Lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews. 1995; 8(4); 557-584.
|
